New immune cell therapy tested for devastating muscle disease
Disease control
Recruiting now
This early-stage study is testing a new type of treatment called CD19-BCMA CAR-T therapy for adults with severe, treatment-resistant myasthenia gravis (MG). The main goals are to see if the treatment is safe and to find the best dose. Researchers will track side effects and check…
Phase: PHASE1 • Sponsor: Ting Chang, MD • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC